3-(N-Arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2)

Soo Hyuk Choi, Luisa Quinti, Aleksey G. Kazantsev, Richard B. Silverman

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Inhibition of sirtuin 2 (SIRT2) is known to be protective against the toxicity of disease proteins in Parkinson's and Huntington's models of neurodegeneration. Previously, we developed SIRT2 inhibitors based on the 3-(N-arylsulfamoyl)benzamide scaffold, including3-(N-(4-bromophenyl)sulfamoyl)- N-(4-bromophenyl)benzamide(C2-8, 1a), which demonstrated neuroprotective effects in a Huntington's mouse model, but had low potency of SIRT2 inhibition. Here we report that N-methylation of 1a greatly increases its potency and results in excellent selectivity for SIRT2 over SIRT1 and SIRT3 isoforms. Structure-activity relationships observed for 1a analogs and docking simulation data suggest that the para-substituted amido moiety of these compounds could occupy two potential hydrophobic binding pockets in SIRT2. These results provide a direction for the design of potent drug-like SIRT2 inhibitors.

Original languageEnglish
Pages (from-to)2789-2793
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Issue number8
Publication statusPublished - 2012 Apr 15

Bibliographical note

Funding Information:
The authors are grateful to the National Institutes of Health ( 5U01NS066912 ) for financial support of this research.

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of '3-(N-Arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2)'. Together they form a unique fingerprint.

Cite this